About Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals (NASDAQ:SLRX) focuses on developing innovative cancer therapies. Headquartered in Houston, the company centers its efforts on advancing treatments for rare, high-need cancers. Its main pipeline includes experimental drugs like seclidemstat, aimed at targeting specific cancer pathways for conditions such as Ewing sarcoma and other solid tumors. Salarius prioritizes transforming how these aggressive cancers are treated, providing new hope for patients with limited options. The company's objectives align with bringing cutting-edge treatments from the lab to the clinic, with a firm commitment to improving survival rates and quality of life for cancer patients. Through ongoing research, partnerships, and clinical trials, Salarius continues to expand its understanding and application of targeted cancer therapies.
Snapshot
Operations
Products and/or services of Salarius Pharmaceuticals Inc
- Seclidemstat is a lead investigational drug targeting lysine-specific demethylase 1 (LSD1) for the treatment of Ewing sarcoma and other cancers with high unmet needs.
- Clinical trials focus on expanding Seclidemstat's efficacy profile, investigating its potential use in combination therapies for various cancer types to enhance its therapeutic benefits.
- Research initiatives aim to discover and develop additional novel cancer therapies, leveraging expertise in epigenetic target identification to address critical areas in oncology.
- Collaborations and partnerships are key to accelerating pipeline development, providing access to the latest scientific advancements and facilitating novel therapeutic discovery and commercialization.
- Business development efforts focus on securing strategic alliances, funding, and licensure opportunities to strengthen and expand the oncology-focused portfolio.
- Community engagement and awareness programs are in place to educate the public about ongoing research projects and clinical trials related to cancer treatment advancements.
Salarius Pharmaceuticals Inc executive team
- Mr. Mark J. Rosenblum CPAExecutive VP & CFO
- Mr. Frederick E. Pierce IICEO & Director
- Dr. Barbara Hibner Ph.D.Chief Scientific Officer & Director
- Dr. Nadeem Q. Mirza M.D., M.P.H.Senior Vice President of Clinical Development
- Mr. Peter K. Marschel M.B.A., M.S.Chief Business Officer